Tissue-specific hemostasis in mice.

Department of Immunology, Scripps Research Institute, La Jolla, CA 92037, USA.
Arteriosclerosis Thrombosis and Vascular Biology (Impact Factor: 6.34). 12/2005; 25(11):2273-81. DOI: 10.1161/01.ATV.0000183884.06371.52
Source: PubMed

ABSTRACT Blood coagulation is essential to maintain hemostasis in organisms with a vascular network. Formation of a fibrin-rich clot at a site of vessel injury is a highly complex process that is orchestrated by the coagulation protease cascade. This cascade is regulated by 3 major anticoagulant pathways. Removal of a clot is mediated by the fibrinolytic system. Defects in the regulation of clot formation lead to either hemorrhage or thrombosis. Tissue factor, the primary cellular initiator of blood coagulation, is a transmembrane receptor that is expressed in a tissue-specific manner. The 3 major anticoagulants are tissue factor pathway inhibitor, antithrombin, and protein C, the latter requiring a transmembrane receptor called thrombomodulin for its activation. Tissue factor pathway inhibitor and thrombomodulin are expressed by endothelial cells in a tissue-specific manner, whereas antithrombin and protein C circulate in the plasma. Fibrinolysis requires the activation of plasminogen to plasmin, which is mediated by tissue-type plasminogen activator and urokinase-type plasminogen activator. Interestingly, tissue-type plasminogen activator is expressed by a subset of endothelial cells of discrete size and location. These observations, together with the phenotypes of mice that have defects in the procoagulant, anticoagulant, and fibrinolytic pathways, indicate that hemostasis is regulated in a tissue-specific manner.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is a leading cause of cancer death in women, worldwide. Fortunately, breast cancer is relatively chemosensitive, with recent advances leading to the development of effective therapeutic strategies, significantly increasing disease cure rate. However, disease recurrence and treatment of cases lacking therapeutic molecular targets, such as epidermal growth factor receptor 2 and hormone receptors, referred to as triple-negative breast cancers, still pose major hurdles in the treatment of breast cancer. Thus, novel therapeutic approaches to treat aggressive breast cancers are essential. Blood coagulation factor VII (fVII) is produced in the liver and secreted into the blood stream. Tissue factor (TF), the cellular receptor for fVII, is an integral membrane protein that plays key roles in the extrinsic coagulation cascade. TF is overexpressed in breast cancer tissues. The TF-fVII complex may be formed in the absence of injury, because fVII potentially exists in the tissue fluid within cancer tissues. The active form of this complex (TF-fVIIa) may stimulate the expression of numerous malignant phenotypes in breast cancer cells. Thus, the TF-fVII pathway is a potentially attractive target for breast cancer treatment. To date, a number of studies investigating the mechanisms by which TF-fVII signaling contributes to breast cancer progression, have been conducted. In this review, we summarize the mechanisms controlling TF and fVII synthesis and regulation in breast cancer cells. Our current understanding of the TF-fVII pathway as a mediator of breast cancer progression will be also described. Finally, we will discuss how this knowledge can be applied to the design of future therapeutic strategies.
    World journal of clinical oncology. 12/2014; 5(5):908-920.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Oral anticoagulant play a major role to prevent all major type of vascular related diseases and other cardiovascular risk factors. Anticoagulants prevent the formation of thrombosis and widely used for all major injury. In this re-view we discussed about basic anticoagulant therapy and pharmacology of newer oral anticoagulant Rivaroxaban.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human gliomas are heterogeneous for expression of the procoagulant tissue factor protein.•Tissue factor inhibition delays progression of brain tumors driven by oncogenic EGFR or RAS.•Tissue factor expressed by host cells differently affects subcutaneous and intracranial tumor growth.
    Biochemical and Biophysical Research Communications 10/2014; · 2.28 Impact Factor


1 Download
Available from